ESMO Press Releases

If you require further information regarding any of the press releases listed below, please do not hesitate to contact us (select 'Press & Media').

Filter

Date Title Topic
28 Oct 2016 Media Alert: ESMO Symposium on Immuno-Oncology 2016 Cancer Immunology and Immunotherapy
11 Oct 2016 ESMO 2016 Press Release: Best of ESMO 2016 Congress
10 Oct 2016 ESMO 2016 Press Release: Longer Disease-free Survival in Phase III Trial of Sunitinib as Adjuvant Treatment for Kidney Cancer Genitourinary cancers
10 Oct 2016 ESMO 2016 Press Release: Single-Arm Trials Improve Early Access to Rare Cancer Drugs Translational research
10 Oct 2016 ESMO 2016 Press Release: Financial Difficulties Linked to Worse Outcomes From Cancer Treatment Bioethics, legal and economic issues
10 Oct 2016 ESMO 2016 Press Release: First Feasibility Study of the ESMO-MCBS Scale in Rare Tumour Entities Bioethics, legal and economic issues
10 Oct 2016 ESMO 2016 Press Release: Cabozantinib Improves Progression-free Survival in Metastatic Renal Cell Carcinoma Genitourinary cancers
10 Oct 2016 ESMO 2016 Press Release: MEK Inhibition in KRAS-mutant NSCLC Did Not Improve Survival Lung and other thoracic tumours
10 Oct 2016 ESMO 2016 Press Release: Custirsen Shows no Survival Benefits in Metastatic Prostate Cancer Genitourinary cancers
10 Oct 2016 ESMO 2016 Press Release: Significant Survival Gains from Neoadjuvant Chemotherapy for High-risk Soft Tissue Sarcoma Sarcomas
09 Oct 2016 ESMO 2016 Press Release: Nivolumab Maintains Function and Reduces Symptoms in Relapsed Metastatic Head and Neck Cancer Head and neck cancers
09 Oct 2016 ESMO 2016 Press Release: Greater Patient Selection May be Needed for First Line Nivolumab to Improve Progression-free Survival in Advanced Lung Cancer Lung and other thoracic tumours
09 Oct 2016 ESMO 2016 Press Release: Pembrolizumab New Option for First Line Treatment of Patients with Advanced Lung Cancer and High PD-L1 Expression Lung and other thoracic tumours
09 Oct 2016 ESMO 2016 Press Release: Significant Survival Gains with Atezolizumab vs Docetaxel for Non-Small-Cell Lung Cancer Head and neck cancers
09 Oct 2016 ESMO 2016 Press Release: Ceritinib Provides Longer Progression-free Survival Than Chemotherapy in Phase III Trial of ALK Rearranged Lung Cancer Treatment Lung and other thoracic tumours